Trip killers: Addressing a critical knowledge gap in psychedelic research
Open Access
- 23 March 2026
- journal article
- review article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (5) , 687-702
Abstract
Psychedelic drugs are increasingly under investigation as potential therapeutic agents for mental health conditions and are being increasingly used recreationally. Psychedelic use may result in an episode of intense psychological distress, commonly referred to as a “bad trip.” Bad trips represent a potentially volatile, erratic, and dangerous situation, which may, in extreme cases, require presentation to accident and emergency departments and psychiatric hospital admission. Managing such cases requires careful consideration, with priority given to non-pharmacological strategies. When these measures prove insufficient, an alternative approach may be necessary, one that can effectively attenuate or terminate the psychedelic state and restore psychological stability. Despite clinical relevance, there is no systematic evaluation of pharmacological interventions to terminate such experiences. This review identifies and critically appraises candidate medications with potential utility as abortive agents, including serotonin antagonists, drugs for psychosis, and select drugs for anxiety and depression. We review these agents, their mechanisms of action, pharmacokinetics, safety profiles, and applicability in acute care settings. Binding strength at the molecular level, potency to functionally block receptor-mediated effects, and lack of side effects are key considerations. We conclude by proposing a provisional framework for the pharmacologic management of adverse psychedelic experiences and highlight key priorities for future research.Keywords
This publication has 178 references indexed in Scilit:
- Ayahuasca: A review of historical, pharmacological, and therapeutic aspectsPsychiatry and Clinical Neurosciences Reports, 2023
- Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy SubjectsClinical Pharmacology & Therapeutics, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderJAMA Psychiatry, 2021
- Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances2018
- Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways2017
- Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance‐related psychotic symptomsHuman Psychopharmacology: Clinical and Experimental, 2015
- Pharmacokinetics and Pharmacodynamics of Diphenhydramine 25 mg in Young and Elderly VolunteersThe Journal of Clinical Pharmacology, 1998
- Pharmacokinetics of Ritanserin in Patients Undergoing HemodialysisThe Journal of Clinical Pharmacology, 1991
- The chemical development of selective and specific serotonin S2‐antagonistsDrug Development Research, 1986
- Studies on the Diethylamide of Lysergic Acid (LSD-25)A.M.A. Archives of Neurology & Psychiatry, 1957